These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30835335)

  • 1. Polish regional differences in patient knowledge on atrial fibrillation and its management as well as in patterns of oral anticoagulant prescription.
    Janion-Sadowska A; Sadowski M; Konieczyńska M; Skonieczny G; Metzgier-Gumiela A; Chrapek M; Sobieraj E; Bryk AH; Dębski M; Podolec P; Małecka B; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2019 Jan; 77(4):437-444. PubMed ID: 30835335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
    Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB
    J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
    Jelonek O; Gorczyca I; Bączek M; Kośmider P; Wożakowska-Kapłon B
    Kardiol Pol; 2018; 76(7):1073-1080. PubMed ID: 29441513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
    Simons LA; Ortiz M; Freedman B; Waterhouse BJ; Colquhoun D
    Curr Med Res Opin; 2017 Jul; 33(7):1337-1341. PubMed ID: 28425296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
    Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK
    Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriateness of prescribing profiles and intake adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: analysis of a retrospective longitudinal study using real-world data from Northern Portugal (AF-React Study).
    Silva Pinto S; Henriques TS; Teixeira ASC; Monteiro H; Martins C
    BMJ Open; 2024 Apr; 14(4):e076108. PubMed ID: 38688672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
    Gawałko M; Kapłon-Cieślicka A; Budnik M; Babiarz A; Bodys A; Uliński R; Żochowski M; Peller M; Scisło P; Kochanowski J; Filipiak KJ; Opolski G
    Pol Arch Intern Med; 2017 Dec; 127(12):823-831. PubMed ID: 28972957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
    Hohnloser SH; Basic E; Nabauer M
    Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study.
    Ellis MH; Dotan SG; Hammerman A; Battat E; Derazne E; Avnery O
    Thromb Res; 2018 Sep; 169():140-142. PubMed ID: 30056294
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.